ASTELLAS PHARMA UNSP.ADR (YPHA) — Capital Reinvestment Ratio
Latest as of March 2025:
0.29x
ASTELLAS PHARMA UNSP.ADR (YPHA) has a Capital Reinvestment Ratio of 0.29x as of March 2025, meaning it reinvests 0% of its operating cash flow (€194.51 Billion) in capital expenditures (€57.33 Billion). See YPHA cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.29x
Capex / Operating Cash Flow
Operating Cash Flow
€194.51 Billion
EUR
Capital Expenditures
€57.33 Billion
EUR
Data as of
Mar 2025
Most recent filing
ASTELLAS PHARMA UNSP.ADR Capital Reinvestment Ratio (2022–2025)
This chart tracks ASTELLAS PHARMA UNSP.ADR's Capital Reinvestment Ratio across 4 annual periods.
Annual Capital Reinvestment Ratio for ASTELLAS PHARMA UNSP.ADR (2022–2025)
Year-by-year Capital Reinvestment Ratio for ASTELLAS PHARMA UNSP.ADR from 2022 to 2025. For live market cap and broader valuation context, see YPHA stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.29x | €194.51 Billion | €57.33 Billion | ▼ -38.4% |
| 2024 | 0.48x | €172.47 Billion | €82.50 Billion | ▲ +77.1% |
| 2023 | 0.27x | €327.77 Billion | €88.54 Billion | ▼ -9.0% |
| 2022 | 0.30x | €257.44 Billion | €76.45 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow